Drugs / Dopamine
Dopamine
also known as
A-dopamine · anaerobic dopamine · Blood · ASL-279 · Cardiosteril · Dobutamine a · Dopamin-natterman · Dopamina · +15 more
Small molecule targets ADRB1 via activation
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Neoatricon | — | 2024-05-27 | europa.eu ↗ |
| Label expansion | US (FDA) | DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER | — | 2001-04-17 | fda.gov ↗ |
| Label expansion | US (FDA) | INTROPIN | — | 1981-11-12 | fda.gov ↗ |
| Approved | US (FDA) | INTROPIN | — | 1974-02-25 | fda.gov ↗ |
Trials 20 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06611423 | Oct 2024 → Aug 2025 | impaired renal function disease, systolic heart failure | AstraZeneca | Terminated | No outcome recorded |
| Phase 1 | NCT02053935 | Dec 2013 → Jan 2016 | hyperglycemia, infectious disease with sepsis | Albert Einstein College of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT02009007 | Dec 2012 → Jun 2014 | brain hypoxia - ischemia, hypotensive disorder | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07214285 | Oct 2025 | Parkinson disease | University Hospital, Lille | Completed | No outcome recorded |
| Phase 1/2 | NCT04332276 | Sep 2020 → May 2024 | Parkinson disease | University Hospital, Lille | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04525495 | Apr 2020 → Dec 2022 | — | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT01482559 | Feb 2015 → Sep 2017 | hypotensive disorder, intracerebral hemorrhage | University College Cork | Terminated | No outcome recorded |
| Phase 3 | NCT00314704 | Dec 2003 → Oct 2007 | — | Sepsis Occurrence in Acutely Ill Patients | Completed | No outcome recorded |
| Phase 46 trials | ||||||
| Phase 4 | NCT07633600 | Jun 2026 → Jun 2027 expected | — | Jennifer Cutler | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05658692 | Oct 2022 → Oct 2023 | acute respiratory distress syndrome | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 4 | NCT03892447 | Aug 2019 → Apr 2021 | acute kidney injury | Shengjing Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03170739 | Jun 2017 → Oct 2019 | impaired renal function disease | Tao Zhang | Unknown | No outcome recorded |
| Phase 4 | NCT00484133 | Jun 2007 → Dec 2008 | infectious disease with sepsis | Onze Lieve Vrouwe Gasthuis | Unknown | No outcome recorded |
| Phase 4 | NCT00115115 | Mar 2004 → Dec 2007 | end stage renal failure | University Medical Center Mannheim | Completed | No outcome recorded |
| Phase not applicable6 trials | ||||||
| — | NCT07667829 | Jun 2026 → Dec 2028 expected | chronic thromboembolic pulmonary hypertension, pulmonary arterial hypertension | China National Center for Cardiovascular Diseases | Not yet recruiting | No outcome recorded |
| — | NCT02965963 | Dec 2016 → Jun 2025 | — | University of Alberta | Completed | No outcome recorded |
| — | NCT01866657 | Jun 2013 → Nov 2016 | brain hypoxia - ischemia | University Hospitals Cleveland Medical Center | Terminated | No outcome recorded |
| — | NCT01800877 | Apr 2013 → Dec 2014 | hypotensive disorder | Francois Lamontagne | Completed | No outcome recorded |
| — | NCT01722630 | Mar → Jul 2012 | — | Catholic University of the Sacred Heart | Completed | No outcome recorded |
| — | NCT04753008 | Dec 2010 → Mar 2021 | — | Szeged University | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 35 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00874393 Comparator | Jul 2009 → Dec 2010 | fetal growth restriction, hypotensive disorder | NICHD Neonatal Research Network | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT05670028 Background | Jun 2023 → Jan 2026 | ischemic stroke, vascular insufficiency disorder | Beijing Tiantan Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT06784570 Comparator | Jan 2021 → Mar 2024 | left ventricular failure | Zagazig University | Completed | No outcome recorded |
| Phase 2 | NCT01301313 Comparator | Feb 2011 → Feb 2012 | heart failure | Jose Luis Vazquez Martinez | Terminated | No outcome recorded |
| Phase 2 | NCT01132846 Comparator | Aug 2010 → May 2013 | symptomatic heart failure | Duke University | Completed | No outcome recorded |
| Phase 2/34 trials | ||||||
| Phase 2/3 | NCT03107858 Comparator | Nov 2017 → Jan 2019 | — | Assiut University | Unknown | No outcome recorded |
| Phase 2/3 | NCT02428062 Background | Oct 2014 → Dec 2018 | — | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Suspended | No outcome recorded |
| Phase 2/3 | NCT00953303 Comparator | Jan 2009 → Sep 2011 | heart failure | Hebei Medical University | Completed | No outcome recorded |
| Phase 2/3 | NCT00628160 Comparator | Oct 2006 → Dec 2012 | cirrhosis of liver, infectious disease with sepsis | Hospital Clinic of Barcelona | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT04750070 Comparator | Aug 2021 → Jul 2025 overdue | — | International Centre for Diarrhoeal Disease Research, Bangladesh | Recruiting | No outcome recorded |
| Phase 3 | NCT04536194 Comparator | Oct 2020 → Aug 2021 | congenital heart disease, infant botulism | Children's Hospital of Fudan University | Completed | No outcome recorded |
| Phase 3 | NCT00604019 Comparator | Mar 2003 → Aug 2009 | infectious disease with sepsis | Rush University Medical Center | Completed | No outcome recorded |
| Phase 48 trials | ||||||
| Phase 4 | NCT07322133 Comparator | Jun 2026 → Jun 2027 expected | hypotensive disorder, neonatal respiratory failure, pulmonary hypertension, neonatal | University of California, Davis | Recruiting | No outcome recorded |
| Phase 4 | NCT04243655 Background | Dec 2019 → Oct 2020 | liver disorder | Asian Institute of Gastroenterology, India | Unknown | No outcome recorded |
| Phase 4 | NCT01901809 Comparator | Aug 2013 → Jun 2017 | diastolic heart failure | Johns Hopkins University | Completed | No outcome recorded |
| Phase 4 | NCT01427686 Comparator | Jun 2011 → Feb 2015 | hypotensive disorder | University of Ulm | Unknown | No outcome recorded |
| Phase 4 | NCT01140399 Comparator | Feb → Jun 2011 | heart failure | Niguarda Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT01060293 Comparator | Jul 2009 → Dec 2013 | heart failure | Larissa University Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT00937092 Comparator | Jan 2009 → Jan 2010 | heart failure | Larissa University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02241083 Comparator | Jun 2006 → May 2014 | head and neck cancer | Tampere University Hospital | Completed | No outcome recorded |
| Phase not applicable15 trials | ||||||
| — | NCT07562932 Comparator | May 2026 → May 2031 expected | cardiogenic shock | Chonnam National University Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07111442 Background | Aug 2025 → Aug 2028 expected | renal artery atheroma, renovascular hypertension | Peking University First Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07273526 Comparator | Jun → Dec 2025 overdue | infectious disease with sepsis | Laiba Qamar | Recruiting | No outcome recorded |
| — | NCT06447740 Background | Jun 2024 → Jun 2026 overdue | renal artery atheroma, renovascular hypertension | Peking University First Hospital | Recruiting | No outcome recorded |
| — | NCT05064202 Background | Oct 2023 → Oct 2027 expected | cardiogenic shock | Amsterdam UMC, location VUmc | Not yet recruiting | No outcome recorded |
| — | NCT05732077 Background | Jan 2023 → Mar 2025 | renal artery atheroma, renovascular hypertension | Peking University First Hospital | Unknown | No outcome recorded |
| — | NCT04792424 Background | Apr 2021 → May 2022 | — | Chulalongkorn University | Completed | No outcome recorded |
| — | NCT03780686 Comparator | Apr 2017 → Nov 2018 | — | Ain Shams University | Completed | No outcome recorded |
| — | NCT03020407 Background | Jan 2017 → Jun 2020 | infectious disease with sepsis | Chulalongkorn University | Completed | No outcome recorded |
| — | NCT02726620 Background | Jan → Dec 2017 | hypotensive disorder | Vanderbilt University Medical Center | Completed | No outcome recorded |
| — | NCT02730117 Background | Mar 2016 → Jul 2017 | acute kidney injury | Chulalongkorn University | Completed | No outcome recorded |
| — | NCT01560702 Comparator | Mar 2012 → Sep 2013 | peptic ulcer disease | Zagazig University | Completed | No outcome recorded |
| — | NCT01318278 Comparator | Mar 2011 → Jan 2013 | hypotensive disorder | Baylor College of Medicine | Completed | No outcome recorded |
| — | NCT01882920 Background | Jun 2010 → Jun 2012 | peritoneal neoplasm | Regina Elena Cancer Institute | Completed | No outcome recorded |
| — | NCT00795366 Comparator | Sep 2008 → Sep 2014 | traumatic brain injury | University of Miami | Completed | No outcome recorded |
Press releases naming this drug 23 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-11-09 | AstraZeneca | Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial astrazeneca.com ↗ |
| 2025-08-30 | AstraZeneca | Baxdrostat demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with hard-to-control hypertension in the BaxHTN Phase III trial astrazeneca.com ↗ |
| 2022-12-19 | AbbVie | Cerevel Therapeutics Announces Positive Results in Emraclidine Ambulatory Blood Pressure Monitoring Trial abbvie.com ↗ |
| 2021-06-11 | Novartis Pharmaceuticals | Novartis investigational oral therapy iptacopan (LNP023) shows benefit as monotherapy in treatment-naïve patients with rare and life-threatening blood disorder paroxysmal nocturnal hemoglobinuria novartis.com ↗ |
| 2020-11-19 | Novartis Pharmaceuticals | New data at ASH to reinforce breadth of Novartis hematology portfolio across multiple blood cancers and serious hematologic diseases novartis.com ↗ |
| 2020-05-14 | Novartis Pharmaceuticals | Novartis data at ASCO and EHA showcase bold approaches to reimagine cancer and blood disorders through multiple therapeutic platforms novartis.com ↗ |
| 2019-05-16 | Novartis Pharmaceuticals | Novartis data at ASCO and EHA demonstrate novel approaches to reimagining medicine in cancer and serious blood disorders novartis.com ↗ |
| 2018-12-01 | Novartis Pharmaceuticals | Novartis announces longer-term analyses from pivotal Kymriah® trials that showed durable responses are maintained in patients with advanced blood cancers novartis.com ↗ |
| 2018-06-29 | Novartis Pharmaceuticals | Novartis receives positive CHMP opinion for Kymriah® for treating two aggressive blood cancers, marking important medical advance for patients in Europe novartis.com ↗ |
| 2018-06-15 | Novartis Pharmaceuticals | Novartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients' quality of life novartis.com ↗ |
| 2018-06-15 | Novartis Pharmaceuticals | Novartis study of real-world data concludes Jakavi is associated with a reduction in risk of death and dangerous blood clots for patients with rare blood cancer novartis.com ↗ |
| 2017-11-01 | Novartis Pharmaceuticals | Novartis presents data at ASH for patients with serious blood disorders like lymphoma, leukemia and sickle cell disease novartis.com ↗ |
| 2017-06-19 | Novartis Pharmaceuticals | Sandoz receives approval in Europe for Rixathon® (biosimilar rituximab) to treat blood cancers and immunological diseases novartis.com ↗ |
| 2016-12-05 | Novartis Pharmaceuticals | Novartis survey uncovers real-world burden of myeloproliferative neoplasms (rare blood cancers) on daily activity and ability to work novartis.com ↗ |
| 2016-11-16 | Novartis Pharmaceuticals | Novartis data at ASH and SABCS showcase latest innovations in development for patients with blood disorders and breast cancer novartis.com ↗ |
| 2016-06-10 | Novartis Pharmaceuticals | Novartis highlights long-term safety data of Revolade® in adults with chronic immune thrombocytopenia, a rare blood disorder novartis.com ↗ |
| 2015-07-24 | Novartis Pharmaceuticals | Novartis drug Revolade® recommended by CHMP for EU approval to treat patients with severe aplastic anemia, a serious blood disorder novartis.com ↗ |
| 2015-06-11 | Novartis Pharmaceuticals | Novartis gains FDA approval for Promacta® providing new option for children, ages 6 and older, with chronic ITP, a rare blood disorder novartis.com ↗ |
| 2015-03-17 | Novartis Pharmaceuticals | Novartis receives EU approval for Jakavi® in polycythemia vera, first targeted therapy approved for patients with this rare blood cancer novartis.com ↗ |
| 2015-01-28 | Novartis Pharmaceuticals | Novartis announces study in NEJM showing Jakavi® was superior to standard therapy in rare blood cancer polycythemia vera novartis.com ↗ |
| 2015-01-23 | Novartis Pharmaceuticals | Novartis drug Jakavi® recommended by CHMP for EU approval to treat adults with rare blood cancer polycythemia vera novartis.com ↗ |
| 2013-03-20 | Teva Branded Pharmaceutical Products R&D, Inc. | New Data Show Azilect® (rasagiline tablets) Provided Clinical Benefit in Patients with Early Parkinson’s When Added to Sub-Optimally Controlled Patients on Dopamine Agonist Therapy tevapharm.com ↗ |
| 2012-01-13 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka Pharmaceutical Files New Drug Application for The Dopamine Agonist Transdermal Patch, Rotigotine Patch, in Japan otsuka.co.jp ↗ |
Evidence & citations 28 cited values
Every value below carries the sentence it was read from. 57 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dopamine | “To manipulate the blood pressure within a certain range with hypotensive drugs (e.g. nifedipine, benidipine, captopril, benazepril, irbesartan, labetalol, urapidil) and/or...” NCT05670028 ↗52“In the case of CI \<2.5 l/min/m2 and SVI \<35 ml/m2 with SVV\< 15%, an infusion with dopamine was initiated.” NCT01882920 ↗ “Dopamine (1-20 µg/Kg/min) and/or norepinephrine (0.05-4 µg/Kg/min) until shock resolution” NCT00628160 ↗ “Vasopressors such as Norepinephrine, dopamine, milrinone, dobutamine” NCT02730117 ↗ “Vasopressors such as Norepinephrine, dopamine, milrinone, dobutamine” NCT04792424 ↗ “dopamine and / or dobutamine and / or milrinone and / or adrenaline” NCT01301313 ↗ “pressor support (noradrenaline, doubutamine, dopamine) as needed” NCT04243655 ↗ “Furosemide; torsemide; nitroglycerin; dopamine; Dobutamine” NCT00953303 ↗ “Enoximone, Dobutamine, Dopamine, Milrinone” NCT05064202 ↗ “Norepinephrine, dopamine, epinephrine” NCT03020407 ↗ “phenylephrine, ephedrine, dopamine” NCT01866657 ↗ “levophed, dopamine, phenylephrine)” NCT00795366 ↗ “Dopamine” NCT05658692 ↗ “dopamine” NCT01800877 ↗ “Dopamine” NCT07633600 ↗ |
| Known as | A-dopamine | “The new concept is the intracerebroventricular administration of anaerobic dopamine (A-dopamine) using an abdominal pump connected to a subcutaneous catheter implanted in the...” PMID 39775041 ↗ Jan 2025 |
| Known as | anaerobic dopamine | “The new concept is the intracerebroventricular administration of anaerobic dopamine (A-dopamine) using an abdominal pump connected to a subcutaneous catheter implanted in the...” PMID 39775041 ↗ Jan 20251“Evaluation of Long-term Safety in Parkinsonian Patients With Intracerebroventricular Administration of A-dopamine (Anaerobic Dopamine)” NCT07214285 ↗ |
| Known as | ASL-279 | ChEMBL registry synonym — accepted as the source's own label CHEMBL59 ↗ |
| Known as | Blood | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01560702 ↗ |
| Known as | Cardiosteril | ChEMBL registry synonym — accepted as the source's own label CHEMBL59 ↗ |
| Known as | Dobutamine a | ChEMBL registry synonym — accepted as the source's own label CHEMBL59 ↗ |
| Known as | Dopamin-natterman | ChEMBL registry synonym — accepted as the source's own label CHEMBL59 ↗ |
| Known as | Dopamina | ChEMBL registry synonym — accepted as the source's own label CHEMBL59 ↗ |
| Known as | Dopamine hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL59 ↗ |
| Known as | DOPAMINE HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL59 ↗ |
| Known as | Dopamini hydrochloridum | ChEMBL registry synonym — accepted as the source's own label CHEMBL59 ↗ |
| Known as | Dopmin | ChEMBL registry synonym — accepted as the source's own label CHEMBL59 ↗ |
| Known as | Dynatra | ChEMBL registry synonym — accepted as the source's own label CHEMBL59 ↗ |
| Known as | Inotropin | ChEMBL registry synonym — accepted as the source's own label CHEMBL59 ↗ |
| Known as | Intropin | ChEMBL registry synonym — accepted as the source's own label CHEMBL59 ↗ |
| Known as | Medopa | ChEMBL registry synonym — accepted as the source's own label CHEMBL59 ↗ |
| Known as | Neoatricon | ChEMBL registry synonym — accepted as the source's own label CHEMBL59 ↗ |
| Known as | NSC-169105 | ChEMBL registry synonym — accepted as the source's own label CHEMBL59 ↗ |
| Known as | NSC-173182 | ChEMBL registry synonym — accepted as the source's own label CHEMBL59 ↗ |
| Known as | Oxytyramine | ChEMBL registry synonym — accepted as the source's own label CHEMBL59 ↗ |
| Known as | Sabax dopamin | ChEMBL registry synonym — accepted as the source's own label CHEMBL59 ↗ |
| Known as | Selectajet | ChEMBL registry synonym — accepted as the source's own label CHEMBL59 ↗ |
| Known as | Tensamin | ChEMBL registry synonym — accepted as the source's own label CHEMBL59 ↗ |
| Action | Activate | “Beta-1 adrenergic receptor agonist” CHEMBL59 ↗ |
| Modality | Small molecule | — CHEMBL59 ↗ |
| Route | Intravenous | “dopamine 5μg/kg/min intravenously” NCT00937092 ↗ |
| Target | ADRB1 | “Beta-1 adrenergic receptor agonist” CHEMBL59 ↗ |